CLINICAL_TRIALS
trial_result
· 2016-01-14
Clinical Trial Update: Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma [Phase 2]
Summary
Phase 2 results for vismodegib in younger patients with recurrent or refractory medulloblastoma have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Childhood Medulloblastoma | Phase 2 | Status: COMPLETED | Results posted: 2016-01-14